Tritanrix HB: Opinion on medicine for use outside EU

diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)

Table of contents

Opinion on medicine for use outside the European Union
Withdrawn opinion

Overview

The opinion for Tritanrix HB for use outside the European Union has been withdrawn at the request of the opinion holder.

Opinion details

Product details
Name of medicinal product
Tritanrix HB
Agency opinion number
H-W-3838
Opinion status
Withdrawn opinion
Active substance
  • Bordetella pertussis (inactivated)
  • Diphtheria toxoid
  • hepatitis B surface antigen
  • tetanus toxoid
International non-proprietary name (INN) or common name
diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)
Therapeutic area (MeSH)
  • Hepatitis
  • Tetanus
  • Immunization
  • Meningitis, Haemophilus
  • Whooping Cough
  • Poliomyelitis
  • Diphtheria
Anatomical therapeutic chemical (ATC) code
J07CA05
Publication details
Opinion holder

GlaxoSmithKline Biologicals S.A.
Rue de l'institut 89
1330 Rixensart
Belgium
Date of opinion
19/12/2013

Product information

19/12/2013 Tritanrix HB H-C-W-3838

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards.

Assessment history

How useful was this page?

Add your rating